– Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis – – Additional CALLIPER Data Further Highlight Vidofludimus Calcium’s Favorable Safety and Tolerability Profile;...
– Proven Leader with Deep Multiple Sclerosis Expertise; Played Key Role in the Launch of Ocrevus® – – Will Leverage Senior Global Executive and Commercial Experience to Support Immunic’s Transition Toward a Commercial-Stage Multiple Sclerosis Company – NEW YORK, May 27, 2026 – Immunic, Inc. (Nasdaq:...
– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization – – Played Key Role in the Launch and Commercial Success of Avonex® for Multiple Sclerosis – NEW YORK, May 19, 2026 – Immunic, Inc. (Nasdaq:...
– Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer – – Continued to Execute Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis, with Top-Line Data Expected by End of 2026 – – Raised $200 Million in an Oversubscribed Private Placement,...
NEW YORK, April 30, 2026 – Immunic, Inc. (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor and medical conferences in May: May 4-6 and 12-13: 26th Bio€quity Europe ....
– Proven Leader in Neurology Drug Development, Including for Several Approved Multiple Sclerosis Therapies – – Strong Experience in Advancing Late-Stage Clinical Programs and Obtaining Global Regulatory Approvals, Key to Supporting Vidofludimus Calcium Through Pivotal Development – NEW YORK, April 28, 2026 – Immunic, Inc. (Nasdaq:...
NEW YORK, April 23, 2026 – Immunic , Inc. (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases (the “Company” or “Immunic”), today announced that it will effect a reverse stock split of its outstanding shares of common stock, effective as of 12:01 a.m. Eastern Time on April 27, 2026....
NEW YORK, April 9, 2026 – Immunic, Inc.(Nasdaq: IMUX) ,a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following scientific and medical conferences in April: April 14-16: 8th Annual Neuroimmunology Drug Development Summit ....
NEW YORK, April 1, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on March 27, 2026, informing the company...
– Nearly 40-Year Biopharmaceutical Professional with Deep CNS and Commercial Leadership Experience in Multiple Sclerosis – – Served on Original Team Responsible for the Launch of Copaxone® in the United States – NEW YORK, March 31, 2026 – Immunic, Inc. (Nasdaq:...
– Patent Covers Label-Mandated Dosing Scheme Across All Indications, Including Multiple Sclerosis; Previously Granted by the USPTO in 2023 – – Broad Protection Extends to All Forms of Vidofludimus, Including Its Salts, Solvates and Free Acid – – Multi-Layered Intellectual Property Strategy Expected to Provide Protection at Least Into 2041 in the United...
NEW YORK, March 3, 2026 – Immunic , Inc. (Nasdaq: IMUX) ,a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced participation in the following investor conferences in March: March 8-11: Leerink Partners Global Healthcare Conference....